KRAS and neoplasm: KPC cells carry both, a mutation in the oncogene KRAS (LSL-KrasG12D/+) and in the tumor-suppressor gene P53 (LSL-Trp53R172H/+), which makes the tumor in our experimental model rather aggressive.